Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Pharmaceuticals

Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, adding the approved drug CAPLYTA (lumateperone) and a clinical-stage neuroscience pipeline to J&J's Innovative Medicine business. The deal is expected to accelerate J&J's 2025 sales growth and strengthen its leadership in neuroscience and mental health therapeutics.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Huma Therapeutics Acquires Alcedis GmbH

January 9, 2023

Healthcare Services

Huma Therapeutics Limited has acquired Alcedis GmbH, a German clinical research and technology firm with more than 25 years of experience. The deal combines Huma's digital health and decentralized clinical trial platform with Alcedis' operational clinical trial expertise to create an expanded end-to-end digital clinical trials capability; financial terms were not disclosed.

Johnson & Johnson Completes Acquisition of V‑Wave Ltd.

October 9, 2024

Medical Devices

Johnson & Johnson has completed its acquisition of V‑Wave Ltd., adding V‑Wave’s Ventura Interatrial Shunt to the Johnson & Johnson MedTech portfolio. The transaction was accounted for as an asset acquisition and will result in an in‑process R&D charge of approximately $600 million as J&J expands its cardiovascular and heart‑failure capabilities.